argenex Q2 Earnings Call Highlights

argenex NASDAQ: ARGX reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, as well as early momentum from a newly expanded label in generalized myasthenia gravis.

MarketBeat • 15 hours ago

argenx SE (ARGX) Q2 2026 Earnings Call Transcript

argenx SE (ARGX) Q2 2026 Earnings Call Transcript

Seeking Alpha • 12 hours ago

Argenx's Vyvgart sales jump in second quarter

Belgian-Dutch immunology company argenx said on ​Thursday global sales of its lead ‌drug Vyvgart jumped in the second quarter of 2026 from a year earlier.

Reuters • a day ago

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update.

GlobeNewsWire • Jul 16, 2026

Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company. The collaboration will see argenx get access to Chai's AI platform and apply de novo antibody discovery across therapeutic targets. argenx has built one of biotechnology's most productive antibody engines, combining deep immunology expertise with a high-powered antibody engineering tea.

Business Wire • Jul 15, 2026

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Seeking Alpha • Jul 15, 2026

Are Medical Stocks Lagging Argenx (ARGX) This Year?

Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 13, 2026

FTRE or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jul 7, 2026

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

Investors Business Daily • Jul 6, 2026

Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth

Wells Fargo on Wednesday named the biotech stock a top Q3 tactical pick. An important catalyst looms for Argenx stock.

Investors Business Daily • Jul 1, 2026